Description:
A treatment used for adults with multiple myeloma that came back or did not get better after treatment with at least one line of anticancer therapy that included a proteasome inhibitor and an immunomodulating agent. It is used in patients whose cancer did not respond to treatment with lenalidomide. Carvykti is made using a patient’s T cells (a type of immune system cell). A gene for a special receptor called chimeric antigen receptor (CAR) is added to the T cells in the laboratory. These changed T cells called CAR T cells are grown in large numbers in the laboratory and given to the patient by infusion. Carvykti binds to a protein called BCMA, which is found on myeloma cells and some types of immune cells. This helps the body’s immune system kill cancer cells. Carvykti is a type of cellular immunotherapy called CAR T-cell therapy. Also called ciltacabtagene autoleucel.
